Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Clinical Research Fellow at Dana-Farber Cancer Institute, Visiting Professor at McGill University, shared a post on LinkedIn:
“CLEOPATRA, DB-09, PATINA, HER2CLIMB-05: multiple new first-line options for treating HER2+ MBC, yet no biomarker available to chose between them.
In this analysis, the genomic test HER2DX showed promise in differentiating patients with HER2+ metastatic breast cancer with favorable vs poor prognosis, who may benefit from different treatment approaches.”
Title: Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxane
Authors: Marcin Kubeczko, Sandra Cobo, Rodrigo Sanchez-Bayona, Bartłomiej Pyciński, Jesús Soberino, Ewa Chmielik, Esther Sanfeliu, Maria Rey, Francisco Pardo, Angela Aguirre, Oleguer Castillo, Aleksandra Lesniak, Malgorzata Oczko-Wojciechowska, Esther Carcelero, Barbara Adamo, Maria Vidal, Milana Bergamino, Julia Maues, Guillermo Villacampa, Laia Paré, Patricia Villagrasa, Eva Ciruelos, Aleix Prat, Michal Jarzab, Fara Brasó-Maristany
Read the Full Article in NPJ Breast Cancer.
More posts featuring Paolo Tarantino.